Merck & Co., Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 48/100
What the filing says
Merck completed acquisition of Terns Pharmaceuticals for $6.8B (adding MK-4208, a BCR::ABL1 inhibitor). Q2 sales grew 5% YoY to $16.6B; KEYTRUDA/QLEX sales $8.4B (+5%), WINREVAIR $588M (+75%), Animal Health $1.8B (+8%). FDA approved LIPFENDRA (first once-daily oral PCSK9 inhibitor). Full-year 2026 sales outlook raised to $66.3–67.3B; non-GAAP EPS lowered to $2.66–$2.76 (was $5.04–$5.16) due to $9.6B in total acquisition charges ($5.7B Terns + $9.0B Cidara).
Why this rating
Two large acquisitions ($6.8B + $9.0B Cidara) compress near-term EPS materially; relative to $198B market cap (~3.5–5% of size), meaningful but not transformational. Strong organic growth and regulatory wins offset.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.